Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：1
|
作者：
Shadman, Mazyar [1 ,2 ]
Mawad, Raya [3 ]
Dean, Carol [1 ]
Shannon-Dorcy, Kathleen [1 ]
Sandhu, Vicky [1 ]
Hendrie, Paul C. [2 ]
Scott, Bart L. [1 ,2 ]
Walter, Roland B. [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Pagel, John [1 ,2 ]
Estey, Elihu H. [2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Swedish Med Ctr, Seattle, WA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3732.3732
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Acute Pulmonary Failure During Remission Induction Chemotherapy in Adults With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Al Ameri, Ali
    Koller, Charles
    Kantarjian, Hagop
    Ravandi, Farhad
    Verstovsek, Srdan
    Borthakur, Gautam
    Pierce, Sherry
    Mattiuzzi, Gloria
    CANCER, 2010, 116 (01) : 93 - 97
  • [32] Adaptive Randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS).
    Giles, F
    Kantarjian, H
    Cortes, J
    Tsimberidou, A
    Faderl, S
    Verstovsek, S
    Thomas, D
    Garcia-Manero, G
    Wierda, W
    Ferrajoli, A
    Kornblau, S
    Andreeff, M
    O'Brien, S
    Beran, M
    Estey, E
    BLOOD, 2003, 102 (11) : 253B - 253B
  • [33] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes
    Montesinos, Pau
    de la Rubia, Javier
    Orti, Guillermo
    Sanz, Jaime
    Martinez, David
    Mendoza, Ninotchka
    Scaff, Miguel
    Paciello, Mariliz
    Romero, Monica
    Martin, Guillermo
    Lorenzo, Ignacio
    Martinez, Jesus
    Algarra, Lorenzo
    Jarque, Isidro
    Perez-Sirvent, Mariluz
    Sanz, Guillermo
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 843A - 843A
  • [34] Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia.
    Singhal, S
    Powles, R
    Treleaven, J
    Horton, C
    Hamblin, M
    Zomas, A
    Prendiville, J
    Saso, R
    Mackay, H
    Milan, S
    Mehta, J
    BLOOD, 1995, 86 (10) : 2039 - 2039
  • [35] Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Yamauchi, Takahiro
    Negoro, Eiju
    Arai, Hajime
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Takemura, Haruyuki
    Inai, Kunihiro
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2635 - 2639
  • [36] High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)
    Larson, Sarah M.
    Campbell, Nicholas P.
    Huo, Dezheng
    Artz, Andrew
    Zhang, Yanming
    Gajria, Devika
    Green, Margaret
    Weiner, Howie
    Daugherty, Christopher
    Odenike, Olatoyosi
    Godley, Lucy A.
    Hyjek, Elizabeth
    Gurbuxani, Sandeep
    Thirman, Michael
    Sipkins, Dorothy
    Van Besien, Koen
    Larson, Richard A.
    Stock, Wendy
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 445 - 450
  • [37] IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA
    PHILPOTT, N
    MEHTA, J
    TRELEAVEN, J
    POWLES, R
    LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 127 - 130
  • [38] Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
    Ravandi, Farhad
    Assi, Rita
    Daver, Naval
    Benton, Christopher B.
    Kadia, Tapan
    Thompson, Philip A.
    Borthakur, Gautam
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina
    Takahashi, Koichi
    Kornblau, Steven
    DiNardo, Courtney D.
    Estrov, Zeev
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James
    Sharma, Padmanee
    Pierce, Sherry
    Pike, Allison
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2019, 6 (09): : E480 - E488
  • [39] Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes
    Invernizzi, R
    Pecci, A
    Rossi, G
    Pelizzari, AM
    Giusto, M
    Tinelli, C
    Ascari, E
    HAEMATOLOGICA, 1997, 82 (06) : 660 - 663
  • [40] Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia
    Uchida, Mayako
    Mochizuki, Erika
    Ishida, Shigeru
    Ozawa, Nana
    Yonemitsu, Hiroko
    Ochiai, Hideki
    Nakamura, Hanae
    Kawashiri, Takehiro
    Kato, Koji
    Egashira, Nobuaki
    Akashi, Koichi
    Ieiri, Ichiro
    IN VIVO, 2023, 37 (02): : 924 - 932
12345